Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma.
about
Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patientsHepatocellular Carcinoma and Liver Transplantation: State of the ArtManagement of recurrent hepatocellular carcinoma after liver transplantThe Clinical Significance and Potential Therapeutic Role of GPx3 in Tumor Recurrence after Liver Transplantation.[18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donorUpdate in management of hepatocellular carcinoma in Eastern populationOutcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort.Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinomaTolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinomaLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter.Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma.Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection.Effect of the pringle maneuver on tumor recurrence of hepatocellular carcinoma after curative resection (EPTRH): a randomized, prospective, controlled multicenter trial.Clinical significance and therapeutic value of glutathione peroxidase 3 (GPx3) in hepatocellular carcinomaScoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation.The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma.Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma?Health-related quality of life of 256 recipients after liver transplantationThe International Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline.Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria.Deceased-donor split-liver transplantation in adult recipients: is the learning curve over?Smaller grafts do not imply early recurrence in recipients transplanted for hepatocellular carcinoma: A Chinese experienceManagement of hepatocellular carcinoma: Enlightening the gray zones.Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.Live donors in liver transplantation.Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies.Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation.Liver transplantation for small hepatocellular carcinoma.Liver transplantation for hepatocellular carcinoma: Korean experience.Liver transplantation for hepatocellular carcinoma: the Hong Kong experience.Liver transplantation for hepatocellular carcinoma in the world: the Taiwan experience.Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis.Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.Does living donation have advantages over deceased donation in liver transplantation?Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?
P2860
Q26766049-AEB57241-5617-41A1-ACFA-6F057C6FA889Q26781798-AECC3121-DE63-4917-9CE9-BE131317E1FEQ26997063-354679D5-0008-460B-B2A5-806404B5CBB4Q27300764-FA250294-F046-4A1C-896E-EA811D676308Q27691331-570AF4CC-1EC0-4B6B-A1F6-90386D56C8EAQ28073940-13CDDC74-3178-4DF9-896E-A0FCAE2BC6E7Q28080480-964B553B-B690-4A8A-B595-D828BD6002F7Q30416480-FE26AFED-C1B3-4EEE-9951-F4E6D37F67F9Q30433614-432BED06-60EE-4C7C-9BAF-B9513EBBED08Q30462664-D01EF925-A701-47E4-8BE2-91FEC172CDF2Q33872038-17377054-B471-4046-8E13-BC8E57DD2CF0Q33960740-4DC0ED51-33F5-4BD1-93D3-6AFFEF120302Q34067940-C0DE5C02-B7A7-4C09-AC61-1CD5A87DCDEBQ34263346-5CF1BCE5-E1CE-421C-A552-0B077A5EBDDFQ34264788-926CF8E1-68BE-4E75-BC58-35E146B59547Q34365785-EE98C957-E401-4EB3-AA1B-D12949F1D965Q34957259-3A6E3AE7-DC7D-4494-A42A-23AA8412BFF3Q34977062-1B44012C-307C-43C4-8E8D-04B876C2A8B0Q35133600-F305907F-3BA2-4EC1-A244-6C4B1D5CDC1EQ35779474-531F6915-BAAA-4F9D-8212-BFB9D474AF71Q36111140-1A6B2864-111E-44C7-9147-94CED8AFAC6FQ36285830-85FB79B5-D158-47D8-B729-AE6CABE1F0A8Q36355049-1661659C-3732-4160-B66A-7B56278D62E4Q36643551-15B1D84F-3DD2-4DA1-AEA4-B550E781A882Q36926615-F5518FC6-BE3C-4E7F-AF91-16AD495AB72CQ36937325-985542F3-7A02-42C8-AABE-BC2C6651F2CBQ36955647-9A5BE741-B1E6-405D-B175-B10D96B19400Q36962089-6AF07164-FD95-463B-A9A8-A68FB690892DQ37068256-2228FF05-FCEC-4E57-BE76-0185A94B26AAQ37124591-1C55219A-6D5A-403E-97CF-8364AAA8B599Q37140667-517992A0-71D3-4B34-B67C-20406B36901EQ37190186-A8F25C56-90E0-47D2-BBC7-B5D5BAB14276Q37360177-87751227-2AE7-46E1-9EAB-E45170E2CF6BQ37591234-4843336A-1C17-4DFC-9BF2-8007549ED3DFQ37598591-0CDCA1FF-3927-4F63-8B18-69B87CDD3698Q37598640-B996D1F6-0530-4E8B-9A70-9B77D207F04DQ37636484-1CB31B96-4213-4786-8FCB-D022B4588D13Q37708048-6AFED661-1EC6-4E88-8B81-204493535E96Q37794228-0A5FEA34-6217-4C3C-8668-0B4AE09411D5Q37883997-88849B6D-EEF9-4A77-86F5-272E5313E893
P2860
Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Living donor versus deceased d ...... able hepatocellular carcinoma.
@en
Living donor versus deceased d ...... able hepatocellular carcinoma.
@nl
type
label
Living donor versus deceased d ...... able hepatocellular carcinoma.
@en
Living donor versus deceased d ...... able hepatocellular carcinoma.
@nl
prefLabel
Living donor versus deceased d ...... able hepatocellular carcinoma.
@en
Living donor versus deceased d ...... able hepatocellular carcinoma.
@nl
P2093
P356
P1476
Living donor versus deceased d ...... table hepatocellular carcinoma
@en
P2093
P356
10.1002/BJS.5528
P407
P50
P577
2007-01-01T00:00:00Z